FDA Pressure Likely In Novartis OTC Plant Shutdown, Recalls
This article was originally published in The Tan Sheet
Executive Summary
FDA inspectors were in Novartis Consumer Health’s Lincoln, Neb., plant in December and January, as the company was deciding to halt production and recall products. An inspection report notes 10 observations – eight of them repeats from FDA’s visit in mid-2011.